Navigation Links
Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
Date:8/19/2007

BERKELEY, Calif., Aug. 16 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that the U.S. Patent Office has issued the company a broad composition of matter patent covering the company's proprietary second-generation TLR9 agonists.

The claims cover a broad class of novel TLR9 agonists containing short DNA sequences separated by spacer molecules. These linear chimeric immunomodulatory compounds (CICs), are being developed at Dynavax for application across a wide range of therapeutic categories. The claims cover CICs with or without antigen, and alone or in a pharmaceutical preparation. The current term for this patent expires in June 2022. The patent, U.S. patent No. 7,255,868 B2, was issued August 14, 2007 with inventors Karen Fearon, Dino Dina, M.D., and Stephen Tuck.

According to Dino Dina, M.D., President and Chief Executive Officer, "We developed the second-generation TLR9 agonists specifically to gain broad patent coverage for a full range of products in our pipeline. The issuance of this landmark patent provides broad patent coverage for novel and non-obvious molecules that are completely different from our first generation TLR9 agonists. We have pending applications in this family that we believe have the potential to expand the scope of coverage."

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAV, a hepatitis B vaccine in Phase 3; TOLAMBA, a ragweed allergy immunotherapy; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. Our preclinical work on a vaccine for influenza is partially funded by the NIH. Our colorectal cancer trial and our preclinical hepatitis C therapeutic program are funded by Symphony Dynamo, Inc. While the NIH and SDI provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit http://www.dynavax.com.

This press release contains forward-looking statements that are subject to a number of risks and uncertainties, including statements about the scope of our CIC patent coverage and the potential to obtain expanded coverage. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including; the possibility of litigation or other challenges to the validity or scop of our patents, possible claims against us based on the patent rights of others; and other risks detailed in the "Risk Factors" section of our Quarterly Report on Form 10-Q. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.


'/>"/>
SOURCE Dynavax Technologies Corporation

Copyright©2007 PR Newswire.

Related biology technology :

1. Landmark patent law under attack, Bayh says
2. Changes to U.S. patent law must nurture our culture of innovation
3. WARF questions relevancy of documents used to uphold patent challenge
4. Supreme Court limits foreign reach of U.S. patents
5. High court sends message on patent obviousness
6. Supreme Court ruling seen as blow to WARF stem cell patents
7. Patent licensing: For enforcing companies, the rules have changed
8. Patent ruling doesnt tarnish Wisconsins stem cell leadership
9. Heres why Wisconsins stem cell patents are being challenged
10. WARF is likely to hold on to stem cell patent rights
11. Patent office upholds challenge to WARF stem cell patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences , ... life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer ... “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to ...
Breaking Biology Technology:
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
Breaking Biology News(10 mins):